Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Zelboraf® (vemurafenib) – New indication
November 6, 2017 – The FDA announced the approval of Genentech’s Zelboraf (vemurafenib) for the treatment of patients with Erdheim-Chester disease (ECD) with BRAF V600 mutation.
